Open AccessClinical diagnosis and treatment recommendations for immune checkpoint inhibitor‐related hematological adverse events
Author(s) -
Zhuang Junling,
Du Jianhua,
Guo Xiaoxiao,
Zhou Jiaxin,
Duan Lian,
Qiu Wei,
Si Xiaoyan,
Zhang Li,
Li Yue,
Liu Xiaowei,
Wang Hanping,
Zhou Daobin,
Zhang Li
Publication year - 2020
Publication title -
thoracic cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.823
H-Index - 28
eISSN - 1759-7714
pISSN - 1759-7706
DOI - 10.1111/1759-7714.13281
Subject(s) - medicine , pancytopenia , cytopenia , adverse effect , hemophagocytic lymphohistiocytosis , autoimmune hemolytic anemia , aplastic anemia , immune system , neutropenia , immunology , anemia , bone marrow , chemotherapy , disease
Immune checkpoint inhibitors (ICIs) are able to reactivate the immune system, thereby enhancing the anti‐tumor effects. However, over‐activated T cells may induce immune‐related adverse events (irAEs). Hematological irAEs are rarely reported which mainly represent monolineage cytopenia or pancytopenia, including autoimmune hemolytic anemia (AIHA), immune thrombocytopenia (ITP), neutropenia and aplastic anemia, sometimes even life‐threatening diseases such as hemophagocytic lymphohistiocytosis. Here, the clinical manifestations of hematological irAEs are summarized and recommendations for diagnosis and treatment proposed. Key points Significant findings of the study • Hematological immune‐related adverse events (irAEs) caused by checkpoint inhibitors are rare and may sometimes be life‐threatening. This study summarizes the manifestations of hematological irAEs and proposes preliminary recommendations for diagnosis and treatment. What this study adds • Much still remains unknown regarding hematological irAEs caused by checkpoint inhibitors. This study delineates the overview of hematological irAEs, and provides practical treatment suggestions, in particular addressing the issue of rechallenge.